Join

Compare · ABT vs NBY

ABT vs NBY

Side-by-side comparison of Abbott Laboratories (ABT) and NovaBay Pharmaceuticals Inc. (NBY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABT and NBY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • ABT is the larger of the two at $151.52B, about 11589.5x NBY ($13.1M).
  • Over the past year, ABT is down 34.6% and NBY is down 33.8% - NBY leads by 0.8 points.
  • ABT has hit the wire 4 times in the past 4 weeks while NBY has been quiet.
  • ABT has more recent analyst coverage (25 ratings vs 0 for NBY).
PerformanceABT-33.44%NBY-33.79%
2025-08-05+0.00%2026-06-03
MetricABTNBY
Company
Abbott Laboratories
NovaBay Pharmaceuticals Inc.
Price
$87.01+0.06%
$1.95+21.50%
Market cap
$151.52B
$13.1M
1M return
-0.63%
+32.65%
1Y return
-34.56%
-33.79%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
AMEX
IPO
2007
News (4w)
4
0
Recent ratings
25
0
ABT

Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

NBY

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Latest ABT

Latest NBY